
**Claims**

1. A combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

2. The combination according to claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate salt.

3. The combination according to claim 1 or claim 2, wherein the glucocorticoid is selected from the group consisting of dexamethasone, fluocinolone acetonide and prednisone.

4. The combination according to claim 1 or claim 2, wherein the glucocorticoid is dexamethasone.

5. The combination according to any one of claims 1 to 4, wherein the molar ratio of glucocorticoid to compound of formula I or a pharmaceutically acceptable salt thereof in said combination is from 1:500 to 500:1.

6. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination according to any one of claims 1 to 5.

7. A kit comprising a combination according to any one of claims 1 to 6, and optionally, instructions for treating a patient.

8. The use of the combination according to any one of claims 1 to 5, composition according to claim 6 or kit according to claim 7, in the manufacture of a medicament for the treatment of cancer.

9. The use of a combination, composition or kit for use according to claim 8, wherein said cancer is selected from a hematologic cancer and breast cancer.

10. The use of a combination, composition or kit for use according to claim 9, wherein said hematologic cancer is selected from multiple myeloma, lymphoma and leukemia; or wherein said breast cancer is a triple negative breast cancer.


11. The use of a combination, composition or kit according to any one of claims 8 to 10 wherein said cancer is relapsed and/or refractory.

12. The use of a combination, composition or kit for use according to any one of claims 8 to 11, wherein the glucocorticoid and the compound of formula I or a pharmaceutically acceptable salt thereof are administered concurrently, sequentially or separately.

13. The use of a combination, composition or kit for use according to any one of claims 8 to 12, wherein in said treatment the glucocorticoid is administered at a dosage range of from 0.1 to 1 mg/kg body weight patient.

14. The use of a combination, composition or kit for use according to claim 13 wherein in said treatment the glucocorticoid is administered at a dosage range of from 0.3 to 0.5 mg/kg body weight patient.


15. Use of a compound of formula I or a pharmaceutically acceptable salt thereof:




I,

in the manufacture of a medicament for the treatment of cancer, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is administered in combination with a glucocorticoid.

16. Use of a glucocorticoid in the manufacture of a medicament for the treatment of cancer, wherein the proteasome inhibitor is administered in combination with a compound of formula I or a pharmaceutically acceptable salt thereof:




I.